AGP Executive Report
Last update: 11 hours agoLyme Vaccine Push: Pfizer and Valneva say the EMA has validated the marketing authorization application for their OspA-based Lyme vaccine candidate, moving it into review after Phase 3 results showed over 70% efficacy and no safety red flags. AI Governance & Trust: China doubles down on global AI governance with “principles to action” messaging, while Anthropic faces scrutiny over watermarking Claude outputs to meet EU AI Act transparency rules. OpenAI IPO Buildout: OpenAI plans to nearly double revenue this year and has replaced its chief revenue officer as it ramps up subscription and early ad efforts ahead of a New York Stock Exchange IPO. New York Tech & Health: IBM’s enterprise deal brings AI and cloud tool access to New York State, and a Richmond University Medical Center partnership with WellSky claims faster authorization turnaround (55–60%) to speed care transitions. Public Safety Tech: NYC and other states keep tightening e-bike rules as crashes injure kids, with advocates warning against a patchwork approach that may miss the real risk factors. Markets Watch: Reddit jumps after-hours on S&P 500 inclusion, and Goldman is reportedly in talks to join Nvidia’s massive AI financing initiative. Biosecurity Concern: Researchers used AI to design new bacteriophages that can’t infect humans or animals, but the work raises fresh questions about how to manage AI-made pathogens.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
Pseudo-journalism: Pink-slime
